当前位置： SCI文献检索 > BMC INFECTIOUS DISEASES期刊下所有文献 > Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.

Abstract：

BACKGROUND:In critically ill patients the incidence of invasive fungal infections caused by Candida spp. has increased remarkably. Echinocandins are recommended as initial treatment for invasive fungal infections. The safety and efficacy of micafungin compared to caspofungin is similar, but no comparison is made between anidulafungin and micafungin concerning safety and efficacy. We therefore performed a retrospective study to assess these aspects in critically ill patients with invasive candidiasis. METHODS:All patients in the intensive care unit (ICU) with invasive candidiasis, who were only treated with anidulafungin or micafungin, between January 2012 and December 2014 were retrospectively included. Baseline demographic characteristics, infection characteristics and patient courses were assessed. RESULTS:A total of 63 patients received either anidulafungin (n = 30) or micafungin (n = 33) at the discretion of the attending intensivist. Baseline characteristics were comparable between the two groups, suggesting similar risk for developing invasive candidiasis. Patients with invasive candidiasis and liver failure were more often treated with anidulafungin than micafungin. Response rates were similar for both groups. No difference was observed in 28-day mortality, but 90-day mortality was higher in patients on anidulafungin. Multivariable cox regression analysis showed that age and serum bilirubin were the best parameters for the prediction of 90-day mortality, whereas APACHE II, Candida score and antifungal therapy did not contribute (P > 0.05). None of the patients developed impaired liver function related to antifungal use and no differences were seen in prothrombin time, serum transaminases and bilirubin levels between the groups, after exclusion of patients with liver injury or failure. CONCLUSION:Micafungin can be safely and effectively used in critically ill patients with invasive candidiasis. The observed increased 90-day mortality with anidulafungin can be explained by intensivists unnecessarily avoiding micafungin in patients with liver injury and failure.

journal_name

BMC Infect Dis

journal_title

BMC infectious diseases

authors

van der Geest PJ,Hunfeld NG,Ladage SE,Groeneveld AB

doi

10.1186/s12879-016-1825-3

subject

Has Abstract

pub_date

2016-09-15 00:00:00

pages

490

issn

1471-2334

pii

10.1186/s12879-016-1825-3

journal_volume

pub_type

临床试验,杂志文章

在线工具

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.